Cargando…

Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study

BACKGROUND: α-fetoprotein (AFP) response has been proven a key tumor marker for hepatocellular carcinoma (HCC), but its definition remains controversial. This study aims to characterize AFP trajectories after transarterial chemoembolization (TACE) and examine its impact on clinical outcomes. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Linbin, Shen, Lujun, Wu, Zhixian, Shi, Yanhong, Hou, Peifeng, Xue, Zengfu, Lin, Cheng, Chen, Xiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035711/
https://www.ncbi.nlm.nih.gov/pubmed/35480077
http://dx.doi.org/10.1016/j.eclinm.2022.101391
_version_ 1784693356944687104
author Lu, Linbin
Shen, Lujun
Wu, Zhixian
Shi, Yanhong
Hou, Peifeng
Xue, Zengfu
Lin, Cheng
Chen, Xiong
author_facet Lu, Linbin
Shen, Lujun
Wu, Zhixian
Shi, Yanhong
Hou, Peifeng
Xue, Zengfu
Lin, Cheng
Chen, Xiong
author_sort Lu, Linbin
collection PubMed
description BACKGROUND: α-fetoprotein (AFP) response has been proven a key tumor marker for hepatocellular carcinoma (HCC), but its definition remains controversial. This study aims to characterize AFP trajectories after transarterial chemoembolization (TACE) and examine its impact on clinical outcomes. METHODS: This longitudinal, multicenter, retrospective, cohort study examined data from the electronic medical record system of four hospitals in China between January 1, 2007 to December 31, 2016. A latent class growth mixed model was applied to distinguish potential AFP dynamic changing trajectories. The multivariable Cox models were used to calculate adjusted hazard ratios (aHRs) and 95% CIs for overall survival. Inverse-probability-of-treatment weighted analyses were performed to eliminate unmeasured confounders through marginal structural models. FINDINGS: A total of 881 patients, who had intermediate-stage HCC with AFP repeatedly measured 3 to 10 times, were included in the study. Three distinct trajectories were identified using the latent class growth mixture model: high-rising (25.7%; n = 226), low-stable (58.7%; n = 517), and sharp-falling (AFP serological response, 15.6%; n = 138). Compared with the low-stable class, the aHRs for death were 5.13 (3.71, 7.10) and 0.52 (0.33, 0.81) for the high-rising and sharp-falling class, adjusted by gender, baseline major tumor size, intrahepatic lesions number, and logAFP(smooth). Furthermore, high-rising class had a significantly higher HR in the subgroup of female patients (10.60, 95%CI: 6.29, 17.86), age<55 (6.78, 95%CI: 4.79, 9.59) and Child-Pugh class B (23.01, 95%CI:8.07, 65.63) (P = 0.014, 0.046 and 0.033 for interaction, respectively). Trajectories of AFP had the highest relative importance of each parameter to survival, including largest tumor size, intrahepatic lesions number, Child-Pugh class, and baseline AFP. INTERPRETATION: AFP trajectories were associated with overall survival for intermediate-stage HCC after TACE. FUNDING: The Natural Science Foundation of Fujian Province (Nos. 2018J01352, 2016J01576 and 2016J01586); the Science and Technology Innovation Joint Foundation of Fujian Province (Nos. 2017Y9125).
format Online
Article
Text
id pubmed-9035711
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90357112022-04-26 Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study Lu, Linbin Shen, Lujun Wu, Zhixian Shi, Yanhong Hou, Peifeng Xue, Zengfu Lin, Cheng Chen, Xiong EClinicalMedicine Articles BACKGROUND: α-fetoprotein (AFP) response has been proven a key tumor marker for hepatocellular carcinoma (HCC), but its definition remains controversial. This study aims to characterize AFP trajectories after transarterial chemoembolization (TACE) and examine its impact on clinical outcomes. METHODS: This longitudinal, multicenter, retrospective, cohort study examined data from the electronic medical record system of four hospitals in China between January 1, 2007 to December 31, 2016. A latent class growth mixed model was applied to distinguish potential AFP dynamic changing trajectories. The multivariable Cox models were used to calculate adjusted hazard ratios (aHRs) and 95% CIs for overall survival. Inverse-probability-of-treatment weighted analyses were performed to eliminate unmeasured confounders through marginal structural models. FINDINGS: A total of 881 patients, who had intermediate-stage HCC with AFP repeatedly measured 3 to 10 times, were included in the study. Three distinct trajectories were identified using the latent class growth mixture model: high-rising (25.7%; n = 226), low-stable (58.7%; n = 517), and sharp-falling (AFP serological response, 15.6%; n = 138). Compared with the low-stable class, the aHRs for death were 5.13 (3.71, 7.10) and 0.52 (0.33, 0.81) for the high-rising and sharp-falling class, adjusted by gender, baseline major tumor size, intrahepatic lesions number, and logAFP(smooth). Furthermore, high-rising class had a significantly higher HR in the subgroup of female patients (10.60, 95%CI: 6.29, 17.86), age<55 (6.78, 95%CI: 4.79, 9.59) and Child-Pugh class B (23.01, 95%CI:8.07, 65.63) (P = 0.014, 0.046 and 0.033 for interaction, respectively). Trajectories of AFP had the highest relative importance of each parameter to survival, including largest tumor size, intrahepatic lesions number, Child-Pugh class, and baseline AFP. INTERPRETATION: AFP trajectories were associated with overall survival for intermediate-stage HCC after TACE. FUNDING: The Natural Science Foundation of Fujian Province (Nos. 2018J01352, 2016J01576 and 2016J01586); the Science and Technology Innovation Joint Foundation of Fujian Province (Nos. 2017Y9125). Elsevier 2022-04-16 /pmc/articles/PMC9035711/ /pubmed/35480077 http://dx.doi.org/10.1016/j.eclinm.2022.101391 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Lu, Linbin
Shen, Lujun
Wu, Zhixian
Shi, Yanhong
Hou, Peifeng
Xue, Zengfu
Lin, Cheng
Chen, Xiong
Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study
title Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study
title_full Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study
title_fullStr Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study
title_full_unstemmed Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study
title_short Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study
title_sort trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: a longitudinal, retrospective, multicentre, cohort study
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035711/
https://www.ncbi.nlm.nih.gov/pubmed/35480077
http://dx.doi.org/10.1016/j.eclinm.2022.101391
work_keys_str_mv AT lulinbin trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy
AT shenlujun trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy
AT wuzhixian trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy
AT shiyanhong trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy
AT houpeifeng trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy
AT xuezengfu trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy
AT lincheng trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy
AT chenxiong trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy
AT trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy